2024 Recipient - Oliver Technow, BioVectra
Oliver holds an Industry Master’s Degree from Frankfurt Chamber of Commerce, Frankfurt Germany and has more than 30 years of global pharmaceutical industry experience.
In 1997 he joined Eisai GmbH in Germany and, in 2002, was appointed Director, CNS Business Unit; in 2006, he was appointed Vice President, Head of Global Marketing for Eisai Inc. in the US. In 2011 was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Canada. He became President of BIOVECTRA Inc., in 2015 gaining promotion to his current role of Chief Executive Officer In November 2019. He is a Board Director for BIOTECanada and in 2017 was appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table.